Monitoring patients taking oral carbonic anhydrase inhibitors

American Journal of Ophthalmology

Volumn 130, Issue 2, 2000, Pages 221-223

  Fraunfelder, F T ^a   Bagby, Grover C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

APLASTIC ANEMIA; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; DRUG INDUCED DISEASE; EYE DISEASE; GLAUCOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADMINISTRATION, ORAL; ANEMIA, APLASTIC; BONE MARROW; CARBONIC ANHYDRASE INHIBITORS; DRUG MONITORING; HEMATOLOGIC TESTS; HUMANS;

EID: 0033833803     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(00)00624-3     Document Type: Editorial

References (18)

1. F.T. Fraunfelder S.M. Meyer G.C. Bagby M.W. Dreis Hematologic reactions to carbonic anhydrase inhibitors Am J Ophthalmol 100 1985 79 81
2. R.D. Miller Hematologic reactions to carbonic anhydrase inhibitors (letter) Am J Ophthalmol 100 1985 745 746
3. T. Johnson M.A. Kass Hematologic reactions to carbonic anhydrase inhibitors Am J Ophthalmol 101 1986 128 129
4. A. Zimran E. Beutler Can the risk of acetazolamide-induced aplastic anemia be decreased by periodic monitoring of blood cell counts? (editorial) Am J Ophthalmol 104 1987 654 658
5. L.G. Mogk M.N. Cyrlin Blood dyscrasias and carbonic anhydrase inhibitors Ophthalmology 95 1988 768 771
6. P.R. Lichter Carbonic anhydrase inhibitors, blood dyscrasias, and standard-of-care Ophthalmology 95 1988 711 712
7. K. Doney W. Leisenring R. Storb F.R. Appelbaum Primary treatment of acquired aplastic anemia outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team Ann Intern Med 126 1997 107 115
8. M. Keisu B.E. Wiholm A. Ost O. Mortimer Acetazolamide-associated aplastic anemia J Int Med 228 1990 627 632
9. H. Wandt M. Frank G. Ehninger Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger a prospective comparative trial in 105 patients with acute myeloid leukemia Blood 91 1998 3601 3606
10. G.M. Segal E. Magenis M. Brown Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells J Clin Invest 94 1994 846 852
11. M.A. Whitney G. Royle M.J. Low Germ cell defects and hematopoietic hypersensitivity to (-interferon in mice with a targeted disruption of the Fanconi anemia C gene Blood 88 1996 49 58
12. J.C. Marsh J. Showdry N. Parry-Jones Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia Br J Haematol 104 1999 266 270
13. N.S. Young Immune pathophysiology of acquired aplastic anaemia Eur J Haematol 57 Suppl. 60 1996 55 59
14. G.C. Bagby T-lymphocytes which inhibit granulopoiesis in two neutropenic patients are of the cytotoxic suppressor (OKT3+, OKT8+) subset J Clin Invest 68 1981 1597 1600
15. G.D. Bagby J.H. Lawrence R.C. Neerhout Autoimmune granulopoietic failure identification of T-lymphocyte-mediated inhibition of granulopoiesis and prednisone responsiveness using in vitro techniques N Engl J Med 309 1983 1073 1078
16. S.E. Moroi-Fetters E.N. Metz R.B. Chambers F.H. Davidorf Aplastic anemia with platelet autoantibodies in a patient after taking methazolamide Am J Ophthalmol 110 1990 570 571
17. Unreported data in the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon.
18. F.T. Fraunfelder F.W. Fraunfelder Short-term use of carbonic anhydrase inhibitors and hematologic side effects Arch Ophthalmol 110 1992 446 447